142 related articles for article (PubMed ID: 21211325)
21. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
[TBL] [Abstract][Full Text] [Related]
22. Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence.
Graham JM; Paley MN; Grünewald RA; Hoggard N; Griffiths PD
Brain; 2000 Dec; 123 Pt 12():2423-31. PubMed ID: 11099445
[TBL] [Abstract][Full Text] [Related]
23. Patterns of brain atrophy in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy.
Messina D; Cerasa A; Condino F; Arabia G; Novellino F; Nicoletti G; Salsone M; Morelli M; Lanza PL; Quattrone A
Parkinsonism Relat Disord; 2011 Mar; 17(3):172-6. PubMed ID: 21236720
[TBL] [Abstract][Full Text] [Related]
24. The whole-brain pattern of magnetic susceptibility perturbations in Parkinson's disease.
Acosta-Cabronero J; Cardenas-Blanco A; Betts MJ; Butryn M; Valdes-Herrera JP; Galazky I; Nestor PJ
Brain; 2017 Jan; 140(1):118-131. PubMed ID: 27836833
[TBL] [Abstract][Full Text] [Related]
25. Brain atrophy rates in Parkinson's disease with and without dementia using serial magnetic resonance imaging.
Burton EJ; McKeith IG; Burn DJ; O'Brien JT
Mov Disord; 2005 Dec; 20(12):1571-6. PubMed ID: 16116613
[TBL] [Abstract][Full Text] [Related]
26. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease.
Sasaki M; Shibata E; Tohyama K; Takahashi J; Otsuka K; Tsuchiya K; Takahashi S; Ehara S; Terayama Y; Sakai A
Neuroreport; 2006 Jul; 17(11):1215-8. PubMed ID: 16837857
[TBL] [Abstract][Full Text] [Related]
27. Nigrosome 1 visibility at susceptibility weighted 7T MRI-A dependable diagnostic marker for Parkinson's disease or merely an inconsistent, age-dependent imaging finding?
Gramsch C; Reuter I; Kraff O; Quick HH; Tanislav C; Roessler F; Deuschl C; Forsting M; Schlamann M
PLoS One; 2017; 12(10):e0185489. PubMed ID: 29016618
[TBL] [Abstract][Full Text] [Related]
28. Structural changes in the midbrain with aging and Parkinson's disease: an MRI study.
Sohmiya M; Tanaka M; Aihara Y; Okamoto K
Neurobiol Aging; 2004 Apr; 25(4):449-53. PubMed ID: 15013565
[TBL] [Abstract][Full Text] [Related]
29. Regional brain iron and gene expression provide insights into neurodegeneration in Parkinson's disease.
Thomas GEC; Zarkali A; Ryten M; Shmueli K; Gil-Martinez AL; Leyland LA; McColgan P; Acosta-Cabronero J; Lees AJ; Weil RS
Brain; 2021 Jul; 144(6):1787-1798. PubMed ID: 33704443
[TBL] [Abstract][Full Text] [Related]
30. Quantitative estimation of regional brain iron with magnetic resonance imaging.
Martin WR
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S215-8. PubMed ID: 20082994
[TBL] [Abstract][Full Text] [Related]
31. Magnetic resonance imaging of iron deposition in neurological disorders.
Brass SD; Chen NK; Mulkern RV; Bakshi R
Top Magn Reson Imaging; 2006 Feb; 17(1):31-40. PubMed ID: 17179895
[TBL] [Abstract][Full Text] [Related]
32. Imaging iron stores in the brain using magnetic resonance imaging.
Haacke EM; Cheng NY; House MJ; Liu Q; Neelavalli J; Ogg RJ; Khan A; Ayaz M; Kirsch W; Obenaus A
Magn Reson Imaging; 2005 Jan; 23(1):1-25. PubMed ID: 15733784
[TBL] [Abstract][Full Text] [Related]
33. Brain atrophy and white matter hyperintensities in early Parkinson's disease(a).
Dalaker TO; Larsen JP; Bergsland N; Beyer MK; Alves G; Dwyer MG; Tysnes OB; Benedict RH; Kelemen A; Bronnick K; Zivadinov R
Mov Disord; 2009 Nov; 24(15):2233-41. PubMed ID: 19768730
[TBL] [Abstract][Full Text] [Related]
34. Assessment of cerebral iron content in patients with Parkinson's disease by the susceptibility-weighted MRI.
Wu SF; Zhu ZF; Kong Y; Zhang HP; Zhou GQ; Jiang QT; Meng XP
Eur Rev Med Pharmacol Sci; 2014; 18(18):2605-8. PubMed ID: 25317792
[TBL] [Abstract][Full Text] [Related]
35. The effects of levodopa use on diffusion coefficients in various brain regions in Parkinson's disease.
Degirmenci B; Yaman M; Haktanir A; Albayrak R; Acar M; Caliskan G
Neurosci Lett; 2007 Apr; 416(3):294-8. PubMed ID: 17317000
[TBL] [Abstract][Full Text] [Related]
36. Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis.
Altamura S; Muckenthaler MU
J Alzheimers Dis; 2009; 16(4):879-95. PubMed ID: 19387120
[TBL] [Abstract][Full Text] [Related]
37. A population-specific symmetric phase model to automatically analyze susceptibility-weighted imaging (SWI) phase shifts and phase symmetry in the human brain.
Grabner G; Haubenberger D; Rath J; Beisteiner R; Auff E; Trattnig S; Barth M
J Magn Reson Imaging; 2010 Jan; 31(1):215-20. PubMed ID: 20027591
[TBL] [Abstract][Full Text] [Related]
38. High-field magnetic resonance imaging of brain iron in Alzheimer disease.
Schenck JF; Zimmerman EA; Li Z; Adak S; Saha A; Tandon R; Fish KM; Belden C; Gillen RW; Barba A; Henderson DL; Neil W; O'Keefe T
Top Magn Reson Imaging; 2006 Feb; 17(1):41-50. PubMed ID: 17179896
[TBL] [Abstract][Full Text] [Related]
39. Iron as a vulnerability factor in nigrostriatal degeneration in aging and Parkinson's disease.
Floor E
Cell Mol Biol (Noisy-le-grand); 2000 Jun; 46(4):709-20. PubMed ID: 10875434
[TBL] [Abstract][Full Text] [Related]
40. T1-weighted hyperintensity in basal ganglia at brain magnetic resonance imaging: are different pathologies sharing a common mechanism?
Herrero Hernandez E; Valentini MC; Discalzi G
Neurotoxicology; 2002 Dec; 23(6):669-74. PubMed ID: 12520756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
